Skip to main content
Darkfield

Ransomware victim disclosure

← All victims

MPA Pharma GmbH

listed as MPA Pharma · Claimed by Rhysida · listed 4 hours ago

Today
Age
since listed · data leaked

Status timeline

  1. ListedSep 18, 2026
  2. Data leakeddate unknown

At a glance

Group
Rhysida
Status
Data leaked
Country
Germany
Sector
Healthcare
Listed on leak site
Sep 18, 2026

About the victim

AI dossier — public-source company profile

MPA Pharma GmbH is a German-based international pharmaceutical company specializing in the import, re-import, parallel import, and distribution of patented, generic, and OTC pharmaceuticals, as well as narcotics (BtM) and medical devices. The company also offers contract manufacturing services for third parties and has over 35 years of experience in the pharmaceutical market.

Industry
Pharmaceutical Import & Distribution
Address
Otto-Hahn-Straße 11, 22946 Trittau, Germany

Attack summary

Severity: critical — Confirmed exfiltration of highly sensitive regulated data including: (1) controlled substance (narcotics/BtM) records subject to strict German pharmaceutical law; (2) personal data of executives and employees including government-issued ID; (3) financial credentials (credit cards with CVV); (4) large-scale corporate financial and tax audit data; (5) employee medical records; and (6) IT system credentials. This represents exposure of personally identifiable information at scale combined with regu

Rhysida claims to have exfiltrated approximately 2.9 million files (~5.8 TB) from MPA Pharma, including financial records, government audit documentation, employee and executive personal data, narcotics permits and reconciliations, litigation files, and IT credentials. The group is offering the data for sale with a 7-day auction window.

critical

Data the group says was taken

AI dossier — extracted from the leak post
  • SQL database backups (17.7 million general-ledger rows)
  • Accounting records and financial documents
  • Government audits (customs, corporate tax, social security, wage tax)
  • Narcotics (BtM) permits, reconciliations, and controlled substance records (fentanyl, hydromorphone, oxycodone, tapentadol, cannabis)
  • Executive and employee personal data (ID cards, passports)
  • Credit cards with CVV numbers
  • IT credentials and password files
  • Corporate ownership and beneficial-ownership filings
  • Litigation and settlement agreements
  • Employee medical documents
  • Pharmacovigilance correspondence
  • Pharma vendor contracts (Eli Lilly, AstraZeneca, MSD/Merck)
  • Leadership and organizational charts

What the group claims

MPA Pharma MPA Pharma GmbH is an internationally active, rapidly growing company specializing in the import and trade of high-quality pharmaceuticals, including both patented and generic products. 2,899,290 files, ~5.8 TBPharmaceutical companyCategories: accounting records and database backups, government audits (customs / corporate tax / social security / wage tax),corporate ownership (nominee structure, beneficial-ownership filings, related-party payments), narcotics/BtM records (opioids, cannabis, precursors),litigation files, executive and employee personal data, IT artifacts, pharmacovigilance correspondence.Credit cards with CVV of executives, Oltersdorf ID card valid until 2030, the Pfeiffer letter on the hidden Paranova Pack B.V., UBO passportsSQL backups (17.7 million general-ledger rows), commercial register extract (HRB), organizational chartCredentials (TIER 1) - a list of all password files (values not repeated here, stored in the MPA PASSWORDS report)Government audits - customs 17,011.77 EUR with a breakdown, corporate tax +202,203.18 EUR, social security (DRV) 23,134.96 EUR with a separate case against the managing director, wage-tax auditNarcotics (BtM) - permits (318 04 74), reconciliations of 588 rows / 93 differences, fentanyl, hydromorphone, oxycodone, tapentadol, unexplained remainders of 1-13 units, documentation gap 2017-2020, cannabis up to 22 percent THC, precursorsLitigation - MSD/Merck memo, settlement agreement, Amgros judgment 5,180,043.09 DKK, complaint to the Ministry of Health, arbitration filingPeople, security, pharmacovigilance, bulk financial recordsArtifacts - leadership phone book, employee medical documents, Eli Lilly 2025, AstraZeneca, rebate contracts, a list of all produced reports More

The leak post

captured from the group's site
MPA Pharma GmbH is an internationally active, rapidly growing company specializing in the import and trade of high-quality pharmaceuticals, including both patented and generic products. 2,899,290 files, ~5.8 TBPharmaceutical companyCategories: accounting records and database backups, government audits (customs / corporate tax / social security / wage tax),corporate ownership (nominee structure, beneficial-ownership filings, related-party payments), narcotics/BtM records (opioids, cannabis, precursors),litigation files, executive and employee personal data, IT artifacts, pharmacovigilance correspondence.Credit cards with CVV of executives, Oltersdorf ID card valid until 2030, the Pfeiffer letter on the hidden Paranova Pack B.V., UBO passportsSQL backups (17.7 million general-ledger rows), commercial register extract (HRB), organizational chartCredentials (TIER 1) - a list of all password files (values not repeated here, stored in the MPA PASSWORDS report)Government audits - customs 17,011.77 EUR with a breakdown, corporate tax +202,203.18 EUR, social security (DRV) 23,134.96 EUR with a separate case against the managing director, wage-tax auditNarcotics (BtM) - permits (318 04 74), …

Sources

Source

Indexed 4 hours ago

This page surfaces a public ransomware disclosure indexed by Darkfield. Original posts come from the operator's own leak site; we cross-check against ransomware.live, RansomLook and RansomWatch where applicable. Share this URL freely.

Is this your supplier? Your competitor? You?

Pro plans monitor your domain, corporate emails, and crypto wallets across every new ransomware leak-site post, breach dump and Telegram callout — alerts within 5 minutes.

Disclosure context

About Rhysida

Rhysida is a ransomware group that emerged in June 2023, operating with primarily financial motivations through targeted attacks against critical infrastructure and public sector organizations. The group's origin and potential state affiliations remain unclear, though they operate independently rather than as a traditional Ransomware-as-a-Service model, with limited public documentation regarding connections to other cybercriminal organizations. Rhysida employs double extortion tactics, typically gaining initial access through compromised VPN credentials and exploiting vulnerable public-facing applications before deploying their ransomware payload and exfiltrating sensitive data prior to encryption. The group has demonstrated a particular focus on healthcare and educational institutions, with notable attacks documented by CISA and FBI advisories highlighting their targeting of hospitals and school districts across multiple countries, resulting in significant operational disruptions to critical services. As of late 2024, Rhysida remains an active threat with continued operations targeting organizations primarily in the United States, Canada, and other Western nations, maintaining their focus on high-value sectors where operational disruption can maximize ransom payment likelihood. The group has been linked to 333 public disclosures across our corpus. First observed on a leak site on June 5, 2023; most recent post September 18, 2026. The operation is currently active.

Timeline of this disclosure

  • September 18, 2026MPA Pharma listed by Rhysida on the group's public leak site

Other recent disclosures by Rhysida

Rhysida has been linked to 333 public victims on Darkfield. A sample of the most recent:

See the full Rhysida dossier →

Sector and geography

This disclosure adds to ransomware activity in the Healthcare sector, which has 2,608 disclosures indexed across all operators we track. Geographically, MPA Pharma is reported in Germany, a country with 393 ransomware disclosures in our corpus.

If your organisation is affected

A listing by Rhysida means MPA Pharma appeared on a ransomware extortion site and data attributed to it has been published. If this is your organisation, or a supplier you depend on, the priority is to confirm the intrusion and contain it before the window to act closes.

  • Engage your incident-response team and preserve forensic evidence before remediating — do not wipe affected systems first.
  • Force a password reset and revoke active sessions for exposed accounts; rotate any credentials, API keys or certificates that may have been in the stolen data.
  • Assess regulatory notification duties (GDPR, NIS2, sector regulators) — many carry a 72-hour reporting clock from awareness.
  • Report the incident to your national CERT, CERT-Bund (Germany), as required for your jurisdiction.
  • Monitor for the data appearing on Rhysida's leak site and across paste and breach channels, and brief downstream partners who may be exposed through you.

How we know this. Darkfield monitors public ransomware leak sites continuously, archiving every new disclosure and the data later released against the victim. Each entry on this page is sourced from the operator's own publication and cross-checked against complementary OSINT feeds (RansomLook, ransomware.live, RansomWatch). We do not collect or host stolen data — only the metadata, timestamps and screenshots needed to make the public disclosure searchable and accountable. Records here are corrected when the original post is edited, retracted, or merged with another disclosure.